Episurf Medical AB (STO:EPISB) announced on Wednesday that a European large multi-centre study with 100 Episealer patients has been fully recruited.

These patients are followed-up at three, six, 12, 24 and 60 months post-operatively with clinical scores focusing on pain relief and knee function. The patients have been enrolled since 2014 and the last surgery was recently performed.

Reportedly, the surgeons involved in the clinical study are 11 leading European orthopaedic surgeons. Dr. Med. Johannes Holz from Orthocentrum Hamburg, Germany, has been appointed principal investigator for the study. This study is expected to yield publications on both interim results and final results.

According to the company, all three Episealer knee implants, namely Episealer Condyle Solo, Episealer Trochlea Solo and Episealer Femoral Twin, are included and evaluated in this study. The clinics involved, mostly university-based, are situated in Germany, the UK, Sweden, Norway, Denmark, Belgium and the Netherlands.

Episurf Medical is a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries.